in the absence of a submission from the holder of the marketing authorisation:
nintedanib (Ofev®) is not recommended for use within NHSScotland.
Indication under review: in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice299KB (PDF)
Medicine details
- Medicine name:
- nintedanib (Ofev)
- SMC ID:
- SMC2941
- Indication:
Indicated in children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs).
Indicated in adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Respiratory system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 June 2026